Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

In this phase 2 multicenter study, we evaluated the incorporation of autologous stem cell transplantation (ASCT) into a carfilzomib-lenalidomide-dexamethasone (KRd) regimen for patients with newly diagnosed multiple myeloma (NDMM). Transplant-eligible patients with NDMM received 4 cycles of KRd indu...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Jasielec, Jagoda K., Kubicki, Tadeusz, Raje, Noopur, Vij, Ravi, Reece, Donna, Berdeja, Jesus, Derman, Benjamin A., Rosenbaum, Cara A., Richardson, Paul, Gurbuxani, Sandeep, Major, Sarah, Wolfe, Brittany, Stefka, Andrew T., Stephens, Leonor, Tinari, Kathryn M., Hycner, Tyler, Rojek, Alexandra E., Dytfeld, Dominik, Griffith, Kent A., Zimmerman, Todd M., Jakubowiak, Andrzej J.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7714092/
https://ncbi.nlm.nih.gov/pubmed/32735641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020007522
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares